Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHunter CochranWashington University in St. Louis

Discussion

Loading...

Member takes

Implication

Phase 1b trial finds promising outcomes of mosunetuzumab combined with platinum-based chemotherapy in relapsed large B-cell lymphoma, suggesting potential for improved response rates.

Key Points

  • To assess the safety and efficacy of mosunetuzumab in combination with ICE or DHAX chemotherapy in patients with relapsed/refractory large B-cell lymphoma.
  • Single center, investigator-initiated phase 1b trial enrolling 24 patients with R/R LBCL after previous chemotherapy.
  • Patients received at least 2 cycles of mosun plus platinum-based chemotherapy (DHAX or ICE) followed by response assessment using FDG PET-CT.
  • Safety was primary endpoint; secondary endpoints included overall response rate, complete response rate, progression-free survival, and overall survival.
  • Seventeen patients enrolled, with a median follow-up of 7 months, experiencing manageable safety with low-grade CRS.
  • Overall response rate of 92.3% and complete response rate of 61.5% after treatment, with no progressions post-consolidation.
  • Estimated 12-month PFS is 68% and OS is 76%, indicating promising outcomes in a high-risk population.

Cite This Study

Hunter Cochran (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4f2https://doi.org/10.1182/blood-2025-5508
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial2025 · 1 citations
  2. 2Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study2025 · 6 citations
  3. 3Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  4. 4Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis2025 · 2 citations
  5. 5Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma2025